Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771115 | 0.89 | DGAT1 (0.42) | DGAT1NPC1BACE1KLKB1 | |
| SCHEMBL3376854 | 0.84 | KDM4E (0.48) | DGAT1NPC1NOTUMHTT | |
| SCHEMBL12670976 | 0.81 | HCAR3 (0.40) | NPC1PTGER4KLKB1 | |
| SCHEMBL15778085 | 0.81 | NPC1 (0.39) | DGAT1NPC1NOTUMHTTKLKB1 | |
| SCHEMBL10452108 | 0.80 | NPC1 (0.36) | DGAT1NPC1NOTUM | |
| SCHEMBL15300965 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL29915403 | 0.80 | NPC1 (0.50) | NPC1PTGER4 | |
| SCHEMBL31434000 | 0.79 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL16022788 | 0.79 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL3515085 | 0.79 | MAPT (0.53) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830853-B1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1830853-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | ALCON INC. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071548-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | ALCON, INC. (CH) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ALCON, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | DGAT1 3516/4885NPC1 3288/4885BACE1 4716/4885 |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | DGAT1 3516/4885NPC1 3288/4885BACE1 4716/4885 |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ROCK2, ROCK1, RHOA | DGAT1 3516/4885NPC1 3288/4885BACE1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.